Emerging fungal infections: new patients, new patterns, and new pathogens
DZP Friedman, IS Schwartz - Journal of Fungi, 2019 - mdpi.com
The landscape of clinical mycology is constantly changing. New therapies for malignant and
autoimmune diseases have led to new risk factors for unusual mycoses. Invasive …
autoimmune diseases have led to new risk factors for unusual mycoses. Invasive …
Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management
DJ Epstein, J Dunn, S Deresinski - Open forum infectious …, 2018 - academic.oup.com
Multiple sclerosis therapies include interferons, glatiramer, and multiple immunosuppressive
drugs. Discerning infectious risks of immunosuppressive drugs requires understanding their …
drugs. Discerning infectious risks of immunosuppressive drugs requires understanding their …
Sphingosine‐1‐phosphate receptors and innate immunity
AM Bryan, M Del Poeta - Cellular microbiology, 2018 - Wiley Online Library
Abstract Sphingosine‐1‐phosphate (S1P) is a signalling lipid that regulates many cellular
processes in mammals. One well‐studied role of S1P signalling is to modulate T‐cell …
processes in mammals. One well‐studied role of S1P signalling is to modulate T‐cell …
Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery
P Richardson - Expert Opinion on Drug Discovery, 2021 - Taylor & Francis
Introduction There continues to be an exponential rise in the number of small molecule
drugs that contain either a fluorine atom or a fluorinated fragment. While the unique …
drugs that contain either a fluorine atom or a fluorinated fragment. While the unique …
Molecular mechanisms of immunosenescene and inflammaging: relevance to the immunopathogenesis and treatment of multiple sclerosis
O Perdaens, V Van Pesch - Frontiers in neurology, 2022 - frontiersin.org
Aging is characterized, amongst other features, by a complex process of cellular
senescence involving both innate and adaptive immunity, called immunosenescence and …
senescence involving both innate and adaptive immunity, called immunosenescence and …
The pathobiology of human fungal infections
Human fungal infections are a historically neglected area of disease research, yet they
cause more than 1.5 million deaths every year. Our understanding of the pathophysiology of …
cause more than 1.5 million deaths every year. Our understanding of the pathophysiology of …
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …
Infections in patients receiving multiple sclerosis disease-modifying therapies
E Grebenciucova, A Pruitt - Current neurology and neuroscience reports, 2017 - Springer
Abstract Purpose of Review This paper will systemically review the risk of infections
associated with current disease-modifying treatments and will discuss pre-treatment testing …
associated with current disease-modifying treatments and will discuss pre-treatment testing …
Safety of newer disease modifying therapies in multiple sclerosis
G Jalkh, R Abi Nahed, G Macaron, M Rensel - Vaccines, 2020 - mdpi.com
In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement
L Moiola, V Barcella, S Benatti… - Multiple Sclerosis …, 2021 - journals.sagepub.com
The risk of infection associated with immunomodulatory or immunosuppressive disease-
modifying drugs (DMDs) in patients with multiple sclerosis (MS) has been increasingly …
modifying drugs (DMDs) in patients with multiple sclerosis (MS) has been increasingly …